New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
04:55 EDTLIFE, LIFE, LIFE, CYCC, CYCC, CYCC, BLUE, BLUE, BLUE, PJC, PJC, PJC, STEM, STEM, STEM, ATHX, ATHX, ATHX, NBS, NBS, NBS, ONVO, ONVO, ONVO, CYTX, CYTX, CYTX, ISCO, ISCO, ISCOEBD Group to hold a conference
Biotech Showcase 2014 is being held in San Francisco on January 13-15.
News For LIFE;CYTX;ONVO;NBS;ATHX;STEM;PJC;BLUE;CYCC;ISCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 16, 2015
07:16 EDTATHXAthersys volatility elevated into Phase 2 ischemic stroke trial results
Athersys April call option implied volatility is at 408, May is at 390, July is at 230, October is at 204; compared to its 26-week average of 161 according to Track Data, suggesting large price movement into Phase 2 ischemic stroke trial results to be presented at ESOC.
05:59 EDTATHXStocks with implied volatility above IV index mean; ATHX GMCR
Stocks with implied volatility above IV index mean; Athersys (ATHX) 390, Keurig Green Mountain (GMCR) 53 according to iVolatility.
April 15, 2015
06:07 EDTATHXStocks with implied volatility above IV index mean; ATHX WETF
Subscribe for More Information
April 13, 2015
09:13 EDTBLUEbluebird bio has a conference call hosted by JPMorgan
Subscribe for More Information
08:03 EDTCYTXCytori provides twelve month data update on Scleradec-I trial
Subscribe for More Information
07:38 EDTATHXAthersys volatility elevated into Phase 2 ischemic stroke trial results
Subscribe for More Information
April 9, 2015
07:40 EDTNBSNeoStem announces extension of study under grant from CIRM
NeoStem announced the extension of its study under a 2014 Early Translational grant from the California Institute of Regenerative Medicine, or CIRM, for research leading to the development of a treatment for retinal diseases, including macular degeneration and retinitis pigmentosa. Under the $4M grant made to the University of California, Irvine, NeoStem is entitled, through a subaward, to $1M of new funds adding to the original $0.5M awarded. The goals of the research are to generate three-dimensional retinal tissue, to investigate the ability of adult induced pluripotent stem cells to restore sight in rodent models of retinal degeneration and to make eventual preparations for clinical use of the tissue.
April 8, 2015
15:00 EDTCYTXCytori CEO spinning 'fairy-tale story' to support company, TheStreet says
Subscribe for More Information
10:31 EDTATHXAthersys says Phase 2 ischemic stroke trial results to be presented at ESOC
Athersys announced that Dr. David Hess, a stroke specialist and Chairman of the Department of Neurology at the Medical College of Georgia Regents University, and the lead principal investigator in the study, will present the preliminary results from its Phase 2 clinical trial administering MultiStem for the treatment of ischemic stroke. The presentation will take place at the European Stroke Organization Conference 2015 on Sunday, April 19th starting at 8:50 am in Glasgow, Scotland, United Kingdom. Dr. Hess' presentation will be in the Boisdale Room of the Scottish Exhibition and Conference Centre in Glasgow, in the conference venue.Athersys' double-blind, placebo-controlled Phase 2 clinical trial is being conducted at leading stroke centers across the United States and in the United Kingdom to evaluate the safety and efficacy of its proprietary MultiStem cell therapy in adults who have suffered a severe ischemic stroke and are treated 24-48 hours following the stroke. Dr. Hess served as the lead clinician for the Phase 2 clinical trial, which also included clinical research teams from Oregon Health Sciences University, Houston Methodist Hospital, University of Pittsburgh Medical Center, Cleveland Clinic, Newcastle Upon Tyne and Stoke on Trent, among others. Trial enrollment was completed in December 2014 and this will be the first presentation of the unblinded results.
10:01 EDTONVOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
April 7, 2015
19:10 EDTONVOOn The Fly: After Hours Movers
Subscribe for More Information
16:08 EDTONVOOrganovo initiated with a Buy at Cantor
Subscribe for More Information
11:34 EDTONVOOrganovo jumps almost 8% after announcing pact with L'Oréal
Subscribe for More Information
10:38 EDTNBSNeoStem management to meet with Philadelphia Securities Association
Subscribe for More Information
08:02 EDTCYTXCytori Therapeutics granted orphan drug status for cellular therpeutic in EU
Cytori Therapeutics announced that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products, has designated Cytori’s ECCS-50 cellular therapeutic as an orphan medicinal product for the treatment of scleroderma. This designation marks the first autologous adipose derived cell therapy for scleroderma granted orphan status in the European Union. Cytori is currently working with leading scleroderma centers in France led by the Assistance Publique des Hôpitaux de Marseille to begin a 40 patient EU pivotal trial called SCLERADEC-II. The trial is a follow-up controlled trial to the first SCLERADEC trial published last August. If successful, this trial would potentially lead to EMA approval of Cytori’s lead therapeutic for this indication in the EU, as an ATMP or Advanced Therapy Medicinal Product. Cytori recently received FDA approval for a phase 3 clinical trial with our ECCS-50 therapeutic in 80 patients with scleroderma associated hand dysfunction. This US clinical trial is currently planned to begin enrolling this year and has recently been granted FDA approval to expand the number of centers from 12 to 20 sites. This US clinical data could also be useful to support regulatory approvals and reimbursement in the EU as well as other global markets.
April 6, 2015
14:35 EDTCYTXCytori Therapeutics Chinese FDA approval 'a major win,' says Roth Capital
Subscribe for More Information
12:44 EDTCYTXOn The Fly: Midday Wrap
Subscribe for More Information
11:31 EDTCYTXCytori Therapeutics' Celution receives major win in China, says Roth Capital
Roth Capital said Cytori and partner Lorem Vascular Chinese FDA approval of Celution is a major win. The firm said the approval should move the needle "signficantly" for Celution and views current valuation for Cytori as attractive. Shares are Buy rated with a $6 price target.
09:22 EDTCYTXOn The Fly: Pre-market Movers
HIGHER: Uniqure (QURE), up 44.2% following strategic collaboration with Bristol-Myers (BMY)... Cytori Therapeutics (CYTX), up 22.4% after Lorem Vascular receives regulatory clearance in China... Curis (CRIS), up 8.5% after FDA grants orphan drug designation to CUDC-907 for the treatment of Diffuse Large B-Cell Lymphoma... Capnia (CAPN), up 5.9% after being awarded a $220,000 NIH grant... Tesla (TSLA), up 3.8% after reporting first quarter deliveries up 55% to 10,030 cars... Ariad (ARIA), up 3.4% following approval of Iclusig in Canada... Lumber Liquidators (LL), up 3.1% after being upgraded to Outperform from Market Perform at Raymond James. LOWER: Magnum Hunter (MHR), down 8.9% after being downgraded to Hold from Buy at Wunderlich... Herbalife (HLF), down following CNBC report that federal law enforcement agencies contacted the company regarding its business practices... Qualcomm (QCOM), down 2.2% following a Wall Street Journal report that the Samsung (SSNLF) Galaxy S6 did not have a Qualcomm LTE modem... Skyworks (SWKS), down 2.1% after being downgraded to Equal Weight from Overweight at Stephens.
08:03 EDTCYTXCytori Therapeutics, Lorem Vascular receive regulatory clearance in China
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use